# Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cognitive Impairment Associated With Schizophrenia

> **NCT05182476** · PHASE2 · TERMINATED · sponsor: **Neurocrine Biosciences** · enrollment: 216 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Placebo
- **DRUG:** Luvadaxistat

## Key facts

- **NCT ID:** NCT05182476
- **Lead sponsor:** Neurocrine Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-12-07
- **Primary completion:** 2024-06-28
- **Final completion:** 2024-10-14
- **Target enrollment:** 216 (ACTUAL)
- **Why stopped:** Failed to meet the primary endpoint
- **Last updated:** 2025-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05182476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05182476, "Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cognitive Impairment Associated With Schizophrenia". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT05182476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*